SI0956865T2
(sl)
*
|
1996-08-12 |
2011-04-29 |
Mitsubishi Pharma Corp |
Zdravila, ki obsegajo inhibitor Rho-kinaze
|
WO1999054306A1
(fr)
*
|
1997-03-10 |
1999-10-28 |
Hiroyoshi Hidaka |
Derives isoquinolinesulfonamide et medicaments integrant ces derives comme principe actif
|
US20080233098A1
(en)
*
|
1997-10-31 |
2008-09-25 |
Mckerracher Lisa |
RHO Family Antagonists and Their Use to Block Inhibition of Neurite Outgrowth
|
US6673812B1
(en)
*
|
1998-08-17 |
2004-01-06 |
Senju Pharmaceutical Co., Ltd. |
Preventives/remedies for glaucoma
|
US7169783B2
(en)
*
|
1998-11-02 |
2007-01-30 |
Universite De Montreal |
(+)-Trans-4-(1-aminoethyl)-1-(4-pyridycarbamoyl)-cyclohexane and method for promoting neural growth in the central nervous system and in a patient at a site of neuronal lesion
|
CA2368675C
(en)
*
|
1999-03-25 |
2008-08-12 |
Welfide Corporation |
Agent for prophylaxis and treatment of interstitial pneumonia and pulmonary fibrosis
|
AU3328600A
(en)
*
|
1999-03-25 |
2000-10-16 |
Santen Pharmaceutical Co. Ltd. |
Ocular tension-lowering agents
|
CA2369552A1
(en)
*
|
1999-04-22 |
2000-11-02 |
Hisashi Kai |
Agent for prophylaxis and treatment of angiostenosis
|
AU4144400A
(en)
*
|
1999-04-27 |
2000-11-10 |
Mitsubishi Pharma Corporation |
Preventives/remedies for liver diseases
|
WO2000078351A1
(fr)
*
|
1999-06-18 |
2000-12-28 |
Mitsubishi Pharma Corporation |
Promoteurs de l'osteogenese
|
JP2001081031A
(ja)
*
|
1999-08-30 |
2001-03-27 |
Schering Ag |
溶解性および経口吸収性を改善したベンズアミド誘導体含有製剤
|
AU6865100A
(en)
*
|
1999-09-02 |
2001-04-10 |
Mitsubishi Pharma Corporation |
Osteogenesis promoting agents
|
WO2001022997A1
(fr)
*
|
1999-09-29 |
2001-04-05 |
Mitsubishi Pharma Corporation |
Analgesiques
|
US7217722B2
(en)
|
2000-02-01 |
2007-05-15 |
Kirin Beer Kabushiki Kaisha |
Nitrogen-containing compounds having kinase inhibitory activity and drugs containing the same
|
ATE327993T1
(de)
*
|
2000-03-16 |
2006-06-15 |
Mitsubishi Pharma Corp |
Amid-verbindung und deren verwendung
|
WO2001074391A1
(fr)
*
|
2000-03-31 |
2001-10-11 |
Mitsubishi Pharma Corporation |
Agent de prevention / remedes contre les maladies renales
|
CA2413313C
(en)
*
|
2000-06-23 |
2011-06-14 |
Mitsubishi Pharma Corporation |
Antitumor effect potentiators
|
EP1318984A1
(en)
*
|
2000-09-20 |
2003-06-18 |
MERCK PATENT GmbH |
4-amino-quinazolines
|
MXPA03002411A
(es)
*
|
2000-09-20 |
2003-06-19 |
Merck Patent Gmbh |
4-amino-quinazolinas.
|
JP4582561B2
(ja)
*
|
2000-10-23 |
2010-11-17 |
旭化成ファーマ株式会社 |
移植による血管病変の発生抑制剤
|
JP2002139493A
(ja)
*
|
2000-11-01 |
2002-05-17 |
Sumitomo Pharmaceut Co Ltd |
新規なハイスループット・スクリーニング方法
|
CA2325842C
(en)
|
2000-11-02 |
2007-08-07 |
Lisa Mckerracher |
Methods for making and delivering rho-antagonist tissue adhesive formulations to the injured mammalian central and peripheral nervous systems and uses thereof
|
US20020177207A1
(en)
*
|
2001-03-14 |
2002-11-28 |
Myriad Genetics, Incorporated |
Tsg101-interacting proteins and use thereof
|
US20020132832A1
(en)
*
|
2001-01-05 |
2002-09-19 |
Mills Thomas M. |
Treatment of erectile dysfunction
|
JP2002226375A
(ja)
*
|
2001-01-31 |
2002-08-14 |
Asahi Kasei Corp |
線維化予防、治療剤
|
AU2002322478A1
(en)
*
|
2001-03-02 |
2002-12-16 |
Medimmune, Inc. |
Methods of administering/dosing cd2 antagonists for the prevention and treatment of autoimmune disorders or inflammatory disorders
|
ES2280517T3
(es)
*
|
2001-03-23 |
2007-09-16 |
Bayer Pharmaceuticals Corporation |
Inhibidor de rho-cinasa.
|
PT1370553E
(pt)
*
|
2001-03-23 |
2006-09-29 |
Bayer Corp |
Inibidores de rhoquinase
|
CN101310771B
(zh)
*
|
2001-04-11 |
2012-08-08 |
千寿制药株式会社 |
视觉功能障碍改善剂
|
US7442686B2
(en)
|
2001-04-12 |
2008-10-28 |
Bioaxone Therapeutique Inc. |
Treatment of macular degeneration with ADP-ribosyl transferase fusion protein therapeutic compositions
|
JPWO2002100833A1
(ja)
*
|
2001-06-12 |
2004-09-24 |
住友製薬株式会社 |
Rhoキナーゼ阻害剤
|
JP5042419B2
(ja)
*
|
2001-08-15 |
2012-10-03 |
旭化成ファーマ株式会社 |
骨形成促進剤および骨形成促進組成物
|
US7829566B2
(en)
*
|
2001-09-17 |
2010-11-09 |
Werner Mederski |
4-amino-quinazolines
|
DE10153605A1
(de)
*
|
2001-11-02 |
2003-05-28 |
Morphochem Ag Komb Chemie |
Verwendung von Inhibitoren der Rho-Kinasen zur Stimulation des Nervenwachstums, zur Inhibition der Narbengewebsbildung und/oder Reduktion eines Sekundärschadens
|
AU2002349411A1
(en)
*
|
2001-11-30 |
2003-06-17 |
Asahi Kasei Pharma Corporation |
Remedies for primary pulmonary hypertension
|
FR2833840B1
(fr)
*
|
2001-12-21 |
2010-06-18 |
Rytek |
Methodes et compositions pour le traitement de pathologies respiratoires
|
DE60320933D1
(de)
*
|
2002-01-10 |
2008-06-26 |
Bayer Healthcare Ag |
Rho-kinase inhibitoren
|
JP4423043B2
(ja)
*
|
2002-01-23 |
2010-03-03 |
バイエル ファーマセチカル コーポレーション |
Rho−キナーゼ阻害剤
|
WO2003062225A1
(en)
*
|
2002-01-23 |
2003-07-31 |
Bayer Pharmaceuticals Corporation |
Pyrimidine derivatives as rho-kinase inhibitors
|
GB0206860D0
(en)
*
|
2002-03-22 |
2002-05-01 |
Glaxo Group Ltd |
Compounds
|
US7645878B2
(en)
*
|
2002-03-22 |
2010-01-12 |
Bayer Healthcare Llc |
Process for preparing quinazoline Rho-kinase inhibitors and intermediates thereof
|
EP1500643A4
(en)
*
|
2002-04-03 |
2007-03-28 |
Dainippon Sumitomo Pharma Co |
BENZAMIDE DERIVATIVES
|
US7425618B2
(en)
|
2002-06-14 |
2008-09-16 |
Medimmune, Inc. |
Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
|
US7132100B2
(en)
|
2002-06-14 |
2006-11-07 |
Medimmune, Inc. |
Stabilized liquid anti-RSV antibody formulations
|
US20040028716A1
(en)
*
|
2002-06-14 |
2004-02-12 |
Marks Andrew R. |
Use of Y-27632 as an agent to prevent restenosis after coronary artery angioplasty/stent implantation
|
WO2004006947A1
(en)
*
|
2002-07-12 |
2004-01-22 |
Yihai Cao |
A method for inhibiting vascular permeability and tissue edema
|
US7094789B2
(en)
|
2002-07-22 |
2006-08-22 |
Asahi Kasei Pharma Corporation |
5-substituted isoquinoline derivatives
|
JPWO2004009555A1
(ja)
*
|
2002-07-22 |
2005-11-17 |
旭化成ファーマ株式会社 |
5−置換イソキノリン誘導体
|
DE10233737A1
(de)
*
|
2002-07-24 |
2004-02-05 |
Morphochem Aktiengesellschaft für kombinatorische Chemie |
Verwendung von Modulatoren des Signaltransduktionswegs über die Proteinkinase Fyn zur Behandlung von Tumorerkrankungen
|
AU2003257960A1
(en)
*
|
2002-08-01 |
2004-03-03 |
Caritas St. Elizabeth's Medical Center Of Boston, Inc. |
Cell modulation using a cytoskeletal protein
|
CN100425241C
(zh)
|
2002-08-29 |
2008-10-15 |
参天制药株式会社 |
由Rho激酶抑制剂和前列腺素类物质构成的青光眼治疗剂
|
CA2400996A1
(en)
*
|
2002-09-03 |
2004-03-03 |
Lisa Mckerracher |
1,4-substituted cyclohexane derivatives
|
JPWO2004024717A1
(ja)
*
|
2002-09-12 |
2006-01-05 |
麒麟麦酒株式会社 |
キナーゼ阻害活性を有するイソキノリン誘導体およびそれを含む医薬
|
US20050215601A1
(en)
*
|
2002-09-25 |
2005-09-29 |
Santen Pharmaceutical Co., Ltd. |
Therapeutic agent for rheumatic disease comprising benzamide derivative as active ingredient
|
US8034831B2
(en)
*
|
2002-11-06 |
2011-10-11 |
Celgene Corporation |
Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies
|
US7563810B2
(en)
*
|
2002-11-06 |
2009-07-21 |
Celgene Corporation |
Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
|
CA2506464C
(en)
|
2002-11-18 |
2012-07-31 |
Santen Pharmaceutical Co., Ltd. |
Therapeutic agent for glaucoma comprising rho kinase inhibitor and .beta.-blocker
|
AU2004221792C1
(en)
*
|
2003-03-18 |
2009-09-24 |
Medvet Science Pty. Ltd. |
A method of modulating smooth muscle cell functioning by modulating sphingosine kinase mediated signalling
|
AU2003901270A0
(en)
*
|
2003-03-18 |
2003-04-03 |
Medvet Science Pty. Ltd. |
A method of modulating muscle cell functioning
|
GB2400316A
(en)
*
|
2003-04-10 |
2004-10-13 |
Richard Markoll |
Electromagnetic stimulation in patients with osteoporosis
|
CA2521826C
(en)
|
2003-04-11 |
2013-08-06 |
Jennifer L. Reed |
Recombinant il-9 antibodies and uses thereof
|
JP4566130B2
(ja)
|
2003-04-18 |
2010-10-20 |
千寿製薬株式会社 |
角膜知覚回復剤
|
US20050014783A1
(en)
*
|
2003-05-29 |
2005-01-20 |
Schering Aktiengesellschaft |
Use of Rho-kinase inhibitors in the treatment of aneurysm and cardiac hypertrophy
|
US20110098232A1
(en)
*
|
2003-05-30 |
2011-04-28 |
Zeilig Charles E |
Methods For The Selective Treatment Of Tumors By Calcium-Mediated Induction Of Apoptosis
|
WO2004108142A2
(en)
*
|
2003-06-06 |
2004-12-16 |
The University Of Manchester |
Inhibitors of tip-1 for treatment tissue damage
|
US7160894B2
(en)
|
2003-06-06 |
2007-01-09 |
Asahi Kasei Pharma Corporation |
Tricyclic compound
|
EP1656451A2
(en)
*
|
2003-08-13 |
2006-05-17 |
Children's Hospital Medical Center |
Chimeric peptides for the regulation of gtpases
|
WO2005017160A2
(en)
*
|
2003-08-13 |
2005-02-24 |
Children's Hospital Medical Center |
Mobilization of hematopoietic cells
|
US20060228350A1
(en)
*
|
2003-08-18 |
2006-10-12 |
Medimmune, Inc. |
Framework-shuffling of antibodies
|
AU2004286198C1
(en)
|
2003-08-18 |
2011-02-24 |
Medimmune, Llc |
Humanization of antibodies
|
US7371850B1
(en)
*
|
2003-08-20 |
2008-05-13 |
Myriad Genetics, Inc. |
Method and composition for reducing expression of ROCK-II
|
TWI344961B
(en)
|
2003-10-15 |
2011-07-11 |
Ube Industries |
Novel indazole derivative
|
WO2005056024A1
(en)
*
|
2003-12-05 |
2005-06-23 |
Children's Hospital Medical Center |
Methods of enhancing stem cell engraftment
|
PL1696920T3
(pl)
|
2003-12-19 |
2015-03-31 |
Plexxikon Inc |
Związki i sposoby opracowywania modulatorów Ret
|
TW200526224A
(en)
*
|
2003-12-22 |
2005-08-16 |
Alcon Inc |
Short form c-Maf transcription factor antagonists for treatment of glaucoma
|
KR20060127043A
(ko)
*
|
2003-12-22 |
2006-12-11 |
알콘, 인코퍼레이티드 |
녹내장성 망막병증 및 시각신경병증의 치료용 약제
|
JP2007515422A
(ja)
*
|
2003-12-22 |
2007-06-14 |
アルコン,インコーポレイテッド |
糖尿病性網膜症および黄斑変性における結晶腔形成の処置のための薬剤
|
CA2556589A1
(en)
*
|
2004-02-24 |
2005-09-01 |
Bioaxone Therapeutique Inc. |
4-substituted piperidine derivatives
|
WO2005094824A1
(en)
*
|
2004-03-25 |
2005-10-13 |
East Carolina University |
Methods of enhancing cancer therapy by protecting nerve cells
|
US20080096238A1
(en)
*
|
2004-03-30 |
2008-04-24 |
Alcon, Inc. |
High throughput assay for human rho kinase activity with enhanced signal-to-noise ratio
|
US20060115870A1
(en)
*
|
2004-03-30 |
2006-06-01 |
Alcon, Inc. |
High throughput assay for human Rho kinase activity
|
WO2005102345A1
(en)
*
|
2004-03-30 |
2005-11-03 |
Alcon, Inc. |
Use of rho kinase inhibitors in the treatment of hearing loss, tinnitus and improving body balance
|
AU2005229015C1
(en)
|
2004-04-02 |
2013-01-17 |
The Regents Of The University Of California |
Methods and compositions for treating and preventing disease associated with alphaVbeta5 integrin
|
WO2005118582A1
(ja)
*
|
2004-06-03 |
2005-12-15 |
Senju Pharmaceutical Co., Ltd. |
アミド化合物を含有する角膜知覚回復剤
|
CA2585717A1
(en)
|
2004-10-27 |
2006-05-04 |
Medimmune Inc. |
Modulation of antibody specificity by tailoring the affinity to cognate antigens
|
FR2879100B1
(fr)
|
2004-12-09 |
2007-07-06 |
Lionel Bueno |
Compositions pour le traitement des pathologies oculaires de surface et de la retine
|
AR054416A1
(es)
|
2004-12-22 |
2007-06-27 |
Incyte Corp |
Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas.
|
JP2008525453A
(ja)
*
|
2004-12-27 |
2008-07-17 |
アルコン,インコーポレイティド |
緑内障と、rhoキナーゼを媒介とした他の疾患および症状を治療するためのアミノピラジン・アナログ
|
US20090029970A1
(en)
*
|
2005-02-16 |
2009-01-29 |
Astellas Pharma Inc. |
Pain remedy containing rock inhibitor
|
EP1869192B1
(en)
|
2005-03-18 |
2016-01-20 |
MedImmune, LLC |
Framework-shuffling of antibodies
|
CR9465A
(es)
|
2005-03-25 |
2008-06-19 |
Surface Logix Inc |
Compuestos mejorados farmacocineticamente
|
AU2006261920A1
(en)
|
2005-06-23 |
2007-01-04 |
Medimmune, Llc |
Antibody formulations having optimized aggregation and fragmentation profiles
|
PT1899322E
(pt)
|
2005-06-28 |
2009-11-09 |
Sanofi Aventis |
Derivados de isoquinolina como inibidores de rho-cinase
|
NI200800025A
(es)
|
2005-07-26 |
2009-03-03 |
|
Derivados de isoquinolona sustituidos con piperidinilo en calidad de inhibidores de rho-quinasa
|
ATE521595T1
(de)
|
2005-07-26 |
2011-09-15 |
Sanofi Sa |
Cyclohexylaminisochinolonderivate als rho-kinase- inhibitor
|
CA2620333A1
(en)
|
2005-08-26 |
2007-03-01 |
Braincells, Inc. |
Neurogenesis by muscarinic receptor modulation
|
EP2258359A3
(en)
|
2005-08-26 |
2011-04-06 |
Braincells, Inc. |
Neurogenesis by muscarinic receptor modulation with sabcomelin
|
WO2007026664A1
(ja)
|
2005-08-30 |
2007-03-08 |
Asahi Kasei Pharma Corporation |
スルホンアミド化合物
|
WO2007026920A2
(en)
|
2005-09-02 |
2007-03-08 |
Astellas Pharma Inc. |
Amide derivatives as rock inhibitors
|
JP4832051B2
(ja)
*
|
2005-10-21 |
2011-12-07 |
学校法人順天堂 |
半月体形成性腎病変治療剤
|
EP2377530A3
(en)
|
2005-10-21 |
2012-06-20 |
Braincells, Inc. |
Modulation of neurogenesis by PDE inhibition
|
EP2111863B1
(en)
|
2005-10-26 |
2012-03-28 |
Asahi Kasei Pharma Corporation |
Fasudil in combination with bosentan for the treament of pulmonary arterial hypertension
|
WO2007053596A1
(en)
|
2005-10-31 |
2007-05-10 |
Braincells, Inc. |
Gaba receptor mediated modulation of neurogenesis
|
US7867999B1
(en)
|
2005-12-22 |
2011-01-11 |
Alcon Research, Ltd. |
Hydroxyamino- and amino-substituted pyridine analogs for treating rho kinase-mediated diseases and conditions
|
CA2629342A1
(en)
*
|
2005-12-22 |
2007-07-05 |
Alcon Research, Ltd. |
(indazol-5-yl)-pyrazines and (1,3-dihydro-indol-2-one)- pyrazines for treating rho kinase-mediated diseases and conditions
|
US20100216734A1
(en)
|
2006-03-08 |
2010-08-26 |
Braincells, Inc. |
Modulation of neurogenesis by nootropic agents
|
JP2009536669A
(ja)
|
2006-05-09 |
2009-10-15 |
ブレインセルス,インコーポレイティド |
アンジオテンシン調節による神経新生
|
EP2026813A2
(en)
|
2006-05-09 |
2009-02-25 |
Braincells, Inc. |
5 ht receptor mediated neurogenesis
|
CN101460477A
(zh)
|
2006-06-08 |
2009-06-17 |
宇部兴产株式会社 |
侧链具有螺环结构的新型吲唑衍生物
|
EP2050449A4
(en)
*
|
2006-07-31 |
2010-10-06 |
Senju Pharma Co |
AQUEOUS LIQUID PREPARATION CONTAINING AN AMIDE
|
WO2008022182A1
(en)
*
|
2006-08-16 |
2008-02-21 |
The Uab Research Foundation |
Methods for promoting coupling between bone formation and resorption
|
PT2292663E
(pt)
|
2006-08-28 |
2013-11-04 |
Kyowa Hakko Kirin Co Ltd |
Anticorpos monoclonais humanos antagonistas específicos de light humano
|
GB0617222D0
(en)
*
|
2006-08-31 |
2006-10-11 |
Vereniging Het Nl Kanker I |
Antibiotics
|
KR20090064418A
(ko)
|
2006-09-08 |
2009-06-18 |
브레인셀즈 인코퍼레이션 |
4-아실아미노피리딘 유도체 포함 조합물
|
US20100184806A1
(en)
|
2006-09-19 |
2010-07-22 |
Braincells, Inc. |
Modulation of neurogenesis by ppar agents
|
WO2008049000A2
(en)
*
|
2006-10-18 |
2008-04-24 |
United Therapeutics Corporation |
Combination therapy for pulmonary arterial hypertension
|
WO2008063888A2
(en)
|
2006-11-22 |
2008-05-29 |
Plexxikon, Inc. |
Compounds modulating c-fms and/or c-kit activity and uses therefor
|
WO2008079945A2
(en)
*
|
2006-12-20 |
2008-07-03 |
University Of South Florida |
Rock inhibitors and uses thereof
|
AR064420A1
(es)
*
|
2006-12-21 |
2009-04-01 |
Alcon Mfg Ltd |
Composiciones farmaceuticas oftalmicas que comprenden una cantidad efectiva de analogos de 6-aminoimidazo[1,2b]piridazinas, utiles para el tratamiento del glaucoma y/o controlar la presion intraocular normal o elevada(iop).
|
JP5405314B2
(ja)
|
2006-12-27 |
2014-02-05 |
サノフイ |
シクロアルキルアミン置換イソキノロン誘導体
|
CA2673920C
(en)
|
2006-12-27 |
2015-03-24 |
Sanofi-Aventis |
Cycloalkylamine substituted isoquinoline derivatives
|
AU2007338408B2
(en)
|
2006-12-27 |
2012-07-26 |
Sanofi-Aventis |
Substituted isoquinoline and isoquinolinone derivatives
|
SI2102164T1
(sl)
|
2006-12-27 |
2011-03-31 |
Sanofi Aventis |
Izokinolinski in izokinolinonski derivati, substituirani s cikloalkilaminom
|
CN101573354B
(zh)
|
2006-12-27 |
2014-02-12 |
塞诺菲-安万特股份有限公司 |
取代的异喹啉类及其作为Rho-激酶抑制剂的用途
|
MX2009005825A
(es)
|
2006-12-27 |
2009-06-16 |
Sanofi Aventis |
Derivados de isoquinolina e isoquinolinona sustituidos en calidad de inhibidores de rho-quinasa.
|
GB2458863B
(en)
*
|
2007-01-17 |
2011-10-12 |
Wisconsin Alumni Res Found |
Improved culture of stem cells
|
US8415372B2
(en)
|
2007-02-27 |
2013-04-09 |
Asahi Kasei Pharma Corporation |
Sulfonamide compound
|
AU2008220104B2
(en)
|
2007-02-28 |
2012-09-27 |
Asahi Kasei Pharma Corporation |
Sulfonamide derivative
|
KR101566171B1
(ko)
|
2007-03-09 |
2015-11-06 |
삼성전자 주식회사 |
디지털 저작권 관리 방법 및 장치
|
JP5456658B2
(ja)
|
2007-03-30 |
2014-04-02 |
メディミューン,エルエルシー |
抗体製剤
|
US20100099640A1
(en)
*
|
2007-05-04 |
2010-04-22 |
Joannes Geuns |
Tissue degeneration protection
|
ES2396795T3
(es)
|
2007-07-02 |
2013-02-27 |
Asahi Kasei Pharma Corporation |
Compuesto de sulfonamida y cirstal del mismo
|
US20100190777A1
(en)
|
2007-07-17 |
2010-07-29 |
Plexxikon Inc. |
Compounds and methods for kinase modulation, and indications therefor
|
CN103931608B
(zh)
*
|
2007-08-29 |
2016-02-03 |
千寿制药株式会社 |
促进角膜内皮细胞粘附的药剂
|
US20110294789A1
(en)
*
|
2008-05-12 |
2011-12-01 |
Amnestix, Inc. |
Compounds for rho kinase inhibition and for improving learning and memory
|
DK2303845T3
(da)
|
2008-06-24 |
2013-12-16 |
Sanofi Sa |
Bi- og polycyklisk substitueret isoquinolin og bi- og polycykliske substituerede isoquinolinderivater som rho-kinasehæmmere
|
RU2538588C2
(ru)
|
2008-06-24 |
2015-01-10 |
Санофи-Авентис |
ЗАМЕЩЕННЫЕ ИЗИХИНОЛИНЫ И ИЗОХИНОЛИНОНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ Rho-КИНАЗЫ
|
MX2010013974A
(es)
|
2008-06-24 |
2011-01-14 |
Sanofi Aventis |
Isoquinolinas e isoquinolinonas 6-sustituidas.
|
WO2010010702A1
(ja)
|
2008-07-24 |
2010-01-28 |
国立大学法人大阪大学 |
軸性近視の予防または治療剤
|
US20110166161A1
(en)
*
|
2008-09-18 |
2011-07-07 |
Astellas Pharma Inc. |
Heterocyclic carboxamide compounds
|
EP2177218A1
(en)
|
2008-10-15 |
2010-04-21 |
Medizinische Universität Wien |
Regenerative therapy
|
EP2177510A1
(en)
|
2008-10-17 |
2010-04-21 |
Universität des Saarlandes |
Allosteric protein kinase modulators
|
US20100216805A1
(en)
|
2009-02-25 |
2010-08-26 |
Braincells, Inc. |
Modulation of neurogenesis using d-cycloserine combinations
|
WO2010114928A2
(en)
|
2009-04-03 |
2010-10-07 |
F.Hoffmann-La Roche Ag |
Compositions and uses thereof
|
US8329724B2
(en)
|
2009-08-03 |
2012-12-11 |
Hoffmann-La Roche Inc. |
Process for the manufacture of pharmaceutically active compounds
|
WO2011021221A2
(en)
|
2009-08-17 |
2011-02-24 |
Reliance Life Sciences Pvt. Ltd. |
Compositions for spinal cord injury
|
CN102741394B
(zh)
|
2009-10-16 |
2016-05-04 |
斯克里普斯研究所 |
多能细胞的诱导
|
ES2633317T3
(es)
|
2009-11-06 |
2017-09-20 |
Plexxikon, Inc. |
Compuestos y métodos para la modulación de quinasas, e indicaciones para ello
|
CN102188697B
(zh)
*
|
2010-03-03 |
2014-11-05 |
中国医学科学院药物研究所 |
重组人Rho激酶在制备药物中的应用
|
WO2011133948A2
(en)
|
2010-04-22 |
2011-10-27 |
Longevity Biotech, Inc. |
Highly active polypeptides and methods of making and using the same
|
US9732319B2
(en)
|
2010-12-22 |
2017-08-15 |
Fate Therapeutics, Inc. |
Cell culture platform for single cell sorting and enhanced reprogramming of iPSCs
|
EP3763740A1
(en)
|
2011-01-26 |
2021-01-13 |
Celldex Therapeutics, Inc. |
Anti-kit antibodies and uses thereof
|
AU2012214762B2
(en)
|
2011-02-07 |
2015-08-13 |
Plexxikon Inc. |
Compounds and methods for kinase modulation, and indications therefor
|
AR085279A1
(es)
|
2011-02-21 |
2013-09-18 |
Plexxikon Inc |
Formas solidas de {3-[5-(4-cloro-fenil)-1h-pirrolo[2,3-b]piridina-3-carbonil]-2,4-difluor-fenil}-amida del acido propano-1-sulfonico
|
EP2628482A1
(en)
|
2012-02-17 |
2013-08-21 |
Academisch Medisch Centrum |
Rho kinase inhiitors for use in the treatment of neuroblastoma
|
WO2013167475A1
(en)
*
|
2012-05-08 |
2013-11-14 |
Syddansk Universitet |
Anabolic compounds for treating and preventing bone loss diseases
|
US9150570B2
(en)
|
2012-05-31 |
2015-10-06 |
Plexxikon Inc. |
Synthesis of heterocyclic compounds
|
EP4063391A1
(en)
|
2012-07-25 |
2022-09-28 |
Celldex Therapeutics, Inc. |
Anti-kit antibodies and uses thereof
|
JP2015533832A
(ja)
|
2012-10-09 |
2015-11-26 |
アイジェニカ バイオセラピューティクス インコーポレイテッド |
抗C16orf54抗体およびその使用方法
|
WO2014145718A2
(en)
|
2013-03-15 |
2014-09-18 |
Longevity Biotech, Inc. |
Peptides comprising non-natural amino acids and methods of making and using the same
|
US20160339018A1
(en)
|
2013-04-24 |
2016-11-24 |
Kyushu University, National University Corporation |
Therapeutic agent for ocular fundus disease
|
WO2014177699A1
(en)
*
|
2013-05-03 |
2014-11-06 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Rhoa (rock) inhibitors for the treatment of enflammatory bowel disease
|
US10100123B2
(en)
|
2013-06-06 |
2018-10-16 |
Pierre Fabre Medicament |
Anti-C10orf54 antibodies and uses thereof
|
KR102362630B1
(ko)
|
2013-08-26 |
2022-02-15 |
바이오엔테크 리서치 앤드 디벨롭먼트 인코포레이티드 |
시알릴-루이스 a에 대한 사람 항체 코드화 핵산
|
PT3114214T
(pt)
|
2014-03-04 |
2024-01-03 |
Fate Therapeutics Inc |
Métodos de reprogramação melhorados e plataformas de cultura celular
|
GB201403775D0
(en)
|
2014-03-04 |
2014-04-16 |
Kymab Ltd |
Antibodies, uses & methods
|
KR102614642B1
(ko)
|
2014-06-04 |
2023-12-19 |
바이오엔테크 리서치 앤드 디벨롭먼트 인코포레이티드 |
강글리오사이드 gd2에 대한 사람 단클론 항체
|
JP2017522016A
(ja)
|
2014-06-27 |
2017-08-10 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
培養哺乳動物輪部幹細胞、その産生方法及びその使用
|
DK3229838T3
(da)
|
2014-12-11 |
2020-10-19 |
Pf Medicament |
Anti-C10orf54-antistoffer og anvendelser deraf
|
US10149856B2
(en)
|
2015-01-26 |
2018-12-11 |
BioAxone BioSciences, Inc. |
Treatment of cerebral cavernous malformations and cerebral aneurysms with rho kinase inhibitors
|
US10106525B2
(en)
|
2015-01-26 |
2018-10-23 |
BioAxone BioSciences, Inc. |
Rho kinase inhibitor BA-1049 (R) and active metabolites thereof
|
US10857157B2
(en)
|
2015-01-26 |
2020-12-08 |
BioAxone BioSciences, Inc. |
Treatment of cerebral cavernous malformations and cerebral aneurysms with rho kinase inhibitors
|
JP6970017B2
(ja)
|
2015-02-09 |
2021-11-24 |
メモリアル スローン ケタリング キャンサー センター |
ヒトa33抗原とdota金属複合体に親和性を有する多重特異性抗体及びその使用
|
HRP20230046T1
(hr)
|
2015-03-03 |
2023-03-03 |
Kymab Limited |
Protutijela, upotreba i postupci
|
AU2016281685B2
(en)
|
2015-06-24 |
2021-08-12 |
Nitto Denko Corporation |
Ionizable compounds and compositions and uses thereof
|
WO2017064119A1
(en)
|
2015-10-13 |
2017-04-20 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of retinal capillary non-perfusion
|
EP4088719A1
(en)
|
2015-10-13 |
2022-11-16 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Methods and pharmaceutical compositions for the treatment of retinal capillary non-perfusion
|
JP7263005B2
(ja)
|
2015-10-16 |
2023-04-24 |
フェイト セラピューティクス,インコーポレイテッド |
基底状態の多能性の誘導及び維持に関するプラットフォーム
|
WO2017096017A1
(en)
|
2015-12-02 |
2017-06-08 |
Stsciences, Inc. |
Antibodies specific to glycosylated btla (b- and t- lymphocyte attenuator)
|
MX2018006613A
(es)
|
2015-12-02 |
2019-01-30 |
Stcube & Co Inc |
Anticuerpos y moleculas que se unen inmunoespecificamente a btn1a1 y los usos terapeuticos de los mismos.
|
EP3534947A1
(en)
|
2016-11-03 |
2019-09-11 |
Kymab Limited |
Antibodies, combinations comprising antibodies, biomarkers, uses & methods
|
US11198680B2
(en)
|
2016-12-21 |
2021-12-14 |
BioAxone BioSciences, Inc. |
Rho kinase inhibitor BA-1049 (R) and active metabolites thereof
|
CA3065301A1
(en)
|
2017-05-31 |
2018-12-06 |
Stcube & Co., Inc. |
Antibodies and molecules that immunospecifically bind to btn1a1 and the therapeutic uses thereof
|
US20200131266A1
(en)
|
2017-05-31 |
2020-04-30 |
Stcube & Co., Inc. |
Methods of treating cancer using antibodies and molecules that immunospecifically bind to btn1a1
|
WO2018226671A1
(en)
|
2017-06-06 |
2018-12-13 |
Stcube & Co., Inc. |
Methods of treating cancer using antibodies and molecules that bind to btn1a1 or btn1a1-ligands
|
WO2019014322A1
(en)
*
|
2017-07-11 |
2019-01-17 |
BioAxone BioSciences, Inc. |
KINASE INHIBITORS FOR THE TREATMENT OF DISEASES
|
JP7256796B2
(ja)
|
2017-10-13 |
2023-04-12 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Thomsen-nouvelle(tn)抗原に対するヒト抗体
|
EP3730138B1
(en)
|
2017-12-21 |
2024-02-14 |
Santen Pharmaceutical Co., Ltd. |
Combination of sepetaprost and ripasudil for use in the prophylaxis or treatment of glaucoma or ocular hypertension
|
WO2020016459A1
(en)
|
2018-07-20 |
2020-01-23 |
Pierre Fabre Medicament |
Receptor for vista
|
EP3843845A4
(en)
|
2018-08-29 |
2022-05-11 |
University Of Massachusetts |
INHIBITION OF PROTEIN KINASE FOR THE TREATMENT OF FRIEDREICH'S ATAXIA
|
UY38427A
(es)
|
2018-10-26 |
2020-05-29 |
Novartis Ag |
Métodos y composiciones para terapia con células oculares
|
CN111116555B
(zh)
*
|
2018-10-30 |
2023-06-02 |
北京盈科瑞创新药物研究有限公司 |
一种Rho激酶抑制剂及其制备方法和应用
|
WO2020193802A1
(en)
|
2019-03-28 |
2020-10-01 |
Fundación De La Comunidad Valenciana Centro De Investigación Príncipe Felipe |
Polymeric conjugates and uses thereof
|
CN115667504A
(zh)
|
2020-04-27 |
2023-01-31 |
诺华股份有限公司 |
用于眼细胞疗法的方法和组合物
|
CN111707831A
(zh)
*
|
2020-07-16 |
2020-09-25 |
首都医科大学附属北京朝阳医院 |
Rock激酶活性在辅助诊断sle以及评价sle病情中的应用
|
US11918581B2
(en)
|
2021-01-11 |
2024-03-05 |
Incyte Corporation |
Combination therapy comprising JAK pathway inhibitor and rock inhibitor
|
CN113262226B
(zh)
*
|
2021-04-19 |
2023-05-16 |
杭州市第一人民医院 |
利舒地尔在制备细菌感染治疗药物中的应用
|
WO2023069949A1
(en)
|
2021-10-18 |
2023-04-27 |
Evia Life Sciences Inc. |
Compositions and methods of use thereof for treating liver fibrosis
|
WO2023067394A2
(en)
|
2021-10-22 |
2023-04-27 |
Evia Life Sciences Inc. |
Methods for making extracellular vesicles, and compositions and methods of use thereof
|
WO2023122213A1
(en)
|
2021-12-22 |
2023-06-29 |
Byomass Inc. |
Targeting gdf15-gfral pathway cross-reference to related applications
|
WO2023147107A1
(en)
|
2022-01-31 |
2023-08-03 |
Byomass Inc. |
Myeloproliferative conditions
|